

Immediate release

9 October 2023

CVS Group Plc

("CVS", the "Company" or the "Group")

Exercise of Options, PDMR Dealing, EBT Share Purchase and Total Voting Rights

CVS, the UK listed veterinary group and a leading provider of veterinary services, announces that on 6 October 2023, options over a total of 107,903 new Ordinary shares of 0.2 pence each (the "New shares") were exercised under the CVS Group 2020 Long Term Incentive Plan ("LTIP 14"), at an exercise price of 0.2 pence.

Richard Fairman, Chief Executive Officer, Ben Jacklin, Deputy CEO, and Robin Alfonso, Chief Financial Officer, exercised options over 41,030, 24,618 and 13,540 Ordinary shares of 0.2p each in the Company ("Ordinary shares") respectively. The balance of the options was exercised by certain other employees of the Company.

On 6 October 2023, the Company was notified by JTC Employer Solutions Trustee Limited, the trustee of the CVS Group Employee Benefit Trust (the "EBT"), that the EBT had purchased a total of 56,896 of the New shares from LTIP 14 option-holders at a volume-weighted average price of £16.17 per Ordinary share. This included the purchase of shares by the EBT from Richard Fairman, Ben Jacklin and Robin Alfonso to meet the costs of exercise incurred by them as PDMR option-holders, including personal taxation, as set out below:

Name	Number of shares sold to EBT	Price
Richard Fairman	19,510	£16.17
Ben Jacklin	11,706	£16.17
Robin Alfonso	6,439	£16.17

The New shares purchased by the EBT are intended to be used to satisfy the exercise of share options by employees. The EBT is a discretionary trust for the benefit of the Company's employees, including the Directors of the Company. The purchase of the New shares by the EBT has been funded from the Company's existing cash reserves. Following this transaction, a total of 57,280 Ordinary shares are held by the EBT, representing approximately 0.08% of the Company's total voting rights.

Admission of the New shares, which rank pari passu in all respects with the Company's existing Ordinary shares, has been satisfied by the Company's block listing admitted to the London Stock Exchange on 15 May 2023.

Following the issue of the New shares, the Company has a total issued share capital of 71,537,662 Ordinary shares each carrying one voting right. The Company holds no Ordinary shares in treasury. Therefore, following the issue of the New shares, the total number of voting rights in the Company will be 71,537,662.

This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Following their respective option exercises, their sales of a portion of the New shares arising and admission of the New shares, the Executive Directors, together with their respective spouses, hold a beneficial interest in the following Ordinary shares in the Company:

Name	Number of shares	Percentage interest in the Company
Richard Fairman	77,501	0.108%
Ben Jacklin	36,714	0.051%
Robin Alfonso	19,252	0.027%

The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.

Contacts:

CVS Group plc
 Richard Fairman, CEO
 Scott Morrison, Company Secretary

via Camarco

Peel Hunt LLP (Nominated Adviser & Broker)
 Adrian Trimmings / Michael Burke / Andrew Clark / Lalit Bose

+44 (0)20 7418 8900

Berenberg (Joint Broker)
 Toby Flaux / Ben Wright / James Thompson / Milo Bonser

+44 (0)20 3207 7800

Camarco (Financial PR)
 Geoffrey Pelham-Lane
 Ginny Pulbrook

+44 (0)7733 124 226
 +44 (0)7961 315 138

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated							
a)	Name	Richard Fairman						
2	Reason for the notification							
a)	Position/status	Chief Executive Officer						
b)	Initial notification /Amendment	Initial Notification						
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor							
a)	Name	CVS Group plc						
b)	LEI	213800J41XDQ2NX48O05						
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted							
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 0.2 pence each GB00B2863827						
b)	Nature of the transaction	i) Exercise of options under LTIP 14 ii) Sale of Ordinary shares arising from exercise						
c)	Price(s) and volume(s)	<table border="1"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>i) Exercise price of 0.2p</td> <td>41,030</td> </tr> <tr> <td>ii) 1616.5321p</td> <td>19,510</td> </tr> </table>	Price(s)	Volume(s)	i) Exercise price of 0.2p	41,030	ii) 1616.5321p	19,510
Price(s)	Volume(s)							
i) Exercise price of 0.2p	41,030							
ii) 1616.5321p	19,510							

d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	6 October 2023
f)	Place of the transaction	i) Outside a trading venue ii) London Stock Exchange, AIM.

1	Details of the person discharging managerial responsibilities / person closely associated							
a)	Name	Ben Jacklin						
2	Reason for the notification							
a)	Position/status	Deputy CEO						
b)	Initial notification /Amendment	Initial Notification						
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor							
a)	Name	CVS Group plc						
b)	LEI	213800J41XDQ2NX48O05						
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted							
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 0.2 pence each GB00B2863827						
b)	Nature of the transaction	i) Exercise of options under LTIP 14 ii) Sale of Ordinary shares arising from exercise						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>i) Exercise price of 0.2p</td> <td>24,618</td> </tr> <tr> <td>ii) 1616.5321p</td> <td>11,706</td> </tr> </tbody> </table>	Price(s)	Volume(s)	i) Exercise price of 0.2p	24,618	ii) 1616.5321p	11,706
Price(s)	Volume(s)							
i) Exercise price of 0.2p	24,618							
ii) 1616.5321p	11,706							

d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	6 October 2023
f)	Place of the transaction	i) Outside a trading venue ii) London Stock Exchange, AIM.

1	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	Robin Alfonso	
2	Reason for the notification		
a)	Position/status	Chief Financial Officer	
b)	Initial notification /Amendment	Initial Notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	CVS Group plc	
b)	LEI	213800J41XDQ2NX48O05	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 0.2 pence each GB00B2863827	
b)	Nature of the transaction	i) Exercise of options under LTIP 14 ii) Sale of Ordinary shares arising from exercise	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		i) Exercise price of 0.2p	13,540 6,439
		ii) 1616.5321p	

d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	6 October 2023
f)	Place of the transaction	i) Outside a trading venue ii) London Stock Exchange, AIM.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCEADENESLDFFA